| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Clinical Nephrology |
* Clinical Research Centre for Rare Diseases "Aldo e Cele Daccò," Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, and Unit of Nephrology, Azienda Ospedaliera Ospedali Riuniti, Bergamo, Italy
Address correspondence to: Dr. Piero Ruggenenti, "Mario Negri" Institute for Pharmacological Research, Negri Bergamo Laboratories, Via Gavazzeni, 11-24125 Bergamo, Italy. Phone: +39-035-319-888; Fax: +39-035-319-331; E-mail: manuelap{at}marionegri.it
Background and Objectives: Rituximab, given in four weekly doses, is a promising treatment for idiopathic membranous nephropathy and other immune-mediated diseases and lymphoproliferative disorders. This multidose regimen, however, may cause hypersensitivity reactions and is extremely expensive. This study was aimed at evaluating whether titrating rituximab to circulating CD20 B cells may improve safety and limit costs of treatment.
Design, Setting, Participants, & Measurements: In a matched-cohort, single-center, controlled study, the outcome of 12 new incident patients who had idiopathic membranous nephropathy and nephrotic syndrome and received a B cell–driven treatment was compared with that of 24 historical reference patients who were given the standard protocol of four weekly doses of 375 mg/m2.
Results: Only one patient needed a second dose to achieve full CD20 cell depletion. At 1 yr, time course of the components of nephrotic syndrome and the proportion of patients who achieved disease remission (25%) was identical in both groups. Persistent CD20 cell depletion was achieved in all patients. Costs for rituximab treatment and hospitalizations totalled 
3770.90 ($4902.20) and 13,977.60 ($18,170.80) with the B cell–driven and the four-dose protocol, respectively. One patient on standard protocol had a severe adverse reaction at second rituximab dose. Thus, B cell titrated as effectively as standard rituximab treatment achieves B cell depletion and idiopathic membranous nephropathy remission but is fourfold less expensive, allowing for more than 10,000, approximately $13,000 in savings per patient.
Conclusions: Avoiding unnecessary reexposure to rituximab is extremely cost-saving and may limit the production of antichimeric antibodies that may increase the risk for adverse reactions and prevent re-treatment of disease recurrences.
This article has been cited by other articles:
|
|
 |
|
  F. C. Fervenza Overcoming Calcineurin Dependence in Membranous Nephropathy: Is Rituximab the Answer? Clin. J. Am. Soc. Nephrol., June 1, 2009; 4(6): 1017 - 1019. [Full Text] [PDF]
|
|
|
|
|
|
A. Segarra, M. Praga, N. Ramos, N. Polanco, I. Cargol, E. Gutierrez-Solis, M. R. Gomez, B. Montoro, and J. Camps Successful Treatment of Membranous Glomerulonephritis with Rituximab in Calcineurin Inhibitor-Dependent Patients Clin. J. Am. Soc. Nephrol., June 1, 2009; 4(6): 1083 - 1088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Bomback, V. K. Derebail, J. G. McGregor, A. V. Kshirsagar, R. J. Falk, and P. H. Nachman Rituximab Therapy for Membranous Nephropathy: A Systematic Review Clin. J. Am. Soc. Nephrol., April 1, 2009; 4(4): 734 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D E Furst, E C Keystone, B Kirkham, R Fleischmann, P Mease, F C Breedveld, J S Smolen, J R Kalden, G R Burmester, J Braun, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008 Ann Rheum Dis, December 1, 2008; 67(Suppl_3): iii2 - iii25. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Coppo Non-steroidal and non-cytotoxic therapies for nephrotic syndrome Nephrol. Dial. Transplant., June 1, 2008; 23(6): 1793 - 1796. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
